Literature DB >> 9559756

Psychotropic drug use during pregnancy: weighing the risks.

L S Cohen1, J F Rosenbaum.   

Abstract

Although psychotropic drugs have not been tested or approved by the Food and Drug Administration for use during pregnancy, some women continue to take these medications while they are pregnant, particularly since mood and anxiety disorders cluster in women during childbearing years. The relative risks and benefits of drug therapy for these women must be weighed with each patient and treatment limited to those situations in which risks to mother and fetus from the disorder are presumed to exceed the risk of drug treatment. Risks of psychotropic drug use during pregnancy include teratogenic effects, direct neonatal toxicity, and the potential for longer term neurobehavioral sequelae. Of growing concern is the risk of untreated psychiatric disorder as it may potentially affect fetoplacental integrity and fetal central nervous system development. Coordination of care with the patient, her husband or partner, and the obstetrician is essential, as is careful medical record documentation when treating pregnant patients with psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559756

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Selective serotonin reuptake inhibitor use and risk of gestational hypertension.

Authors:  Sengwee Toh; Allen A Mitchell; Carol Louik; Martha M Werler; Christina D Chambers; Sonia Hernández-Díaz
Journal:  Am J Psychiatry       Date:  2009-01-02       Impact factor: 18.112

Review 2.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Post-traumatic stress disorder in women: epidemiological and treatment issues.

Authors:  Soraya Seedat; Dan J Stein; Paul D Carey
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Diagnosis and management of depression in primary care: a clinical update and review.

Authors:  Ronald A Remick
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

5.  Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxiety.

Authors:  Tiffany Behringer; Bruce L Rollman; Bea Herbeck-Belnap; Patricia R Houck; Sati Mazumdar; Eleanor Bimla Schwarz
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 6.  Depression during pregnancy.

Authors:  Deirdre Ryan; Lisa Milis; Nicholas Misri
Journal:  Can Fam Physician       Date:  2005-08       Impact factor: 3.275

7.  Psychopharmacologic management of opioid-dependent women during pregnancy.

Authors:  Peter R Martin; Amelia M Arria; Gabriele Fischer; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Peter Selby; Hendrée E Jones
Journal:  Am J Addict       Date:  2009 Mar-Apr

Review 8.  Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  A Review of Postpartum Depression.

Authors:  Christa Andrews-Fike
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-02

10.  More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation.

Authors:  Geetha Desai; Girish N Babu; Ravi P Rajkumar; Prabha S Chandra
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.